Is Semaglutide Legal in the UK? MHRA Authorisations Explained

The authorisations that exist — and the boundary that does not move

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a synthetic analogue of the endogenous incretin hormone GLP-1. Structurally, it resembles the human GLP-1 peptide closely enough to bind its receptor with high affinity, but it carries modifications, including a C18 fatty diacid side chain attached via a linker, that extend its half-life to approximately one week in plasma. That pharmacokinetic profile is what makes a once-weekly dosing schedule clinically viable. The pivotal STEP 1 trial, a randomised, double-blind, placebo-controlled study published in The New England Journal of Medicine in 2021 (Wilding et al., PMID 33567185), reported a mean weight reduction of approximately 14.9% from baseline over 68 weeks in patients receiving semaglutide weekly, versus 2.4% in the placebo group.

That body of clinical evidence produced a cascade of regulatory applications and marketing authorisations worldwide. In the United Kingdom, the regulatory authority responsible for assessing and licensing medicines for human use is the Medicines and Healthcare products Regulatory Agency (MHRA). Since Brexit, the MHRA has licensed medicines for Great Britain independently of the European Medicines Agency, under the Human Medicines Regulations 2012. Semaglutide's legal status therefore depends on which products the MHRA has authorised, in what form and for which indications; anything outside those authorisations has no licence.

Injectable Wegovy — MHRA marketing authorisation, prescription-only

Wegovy is a once-weekly subcutaneous injection of semaglutide, indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as hypertension, dyslipidaemia, type 2 diabetes mellitus, or obstructive sleep apnoea. The MHRA granted Wegovy a Great Britain marketing authorisation following its own scientific assessment. It is classified as a prescription-only medicine (POM) under Schedule 1 of the Prescription Only Medicines Order, meaning it may only be supplied to a patient in response to a written prescription issued by an authorised healthcare professional. A pharmacist cannot dispense it without that prescription, and a patient cannot legally obtain it through any other route in the UK.

The MHRA's public assessment report and product information for Wegovy are available through the agency's medicines database at gov.uk/MHRA. The prescription-only classification reflects the MHRA's determination that semaglutide at this dose requires individual clinical assessment, carries contraindications and interactions that need professional evaluation, and involves risks including gastrointestinal effects, heart rate changes, and potential associations with thyroid C-cell tumours observed in rodent studies, the clinical significance of which requires monitoring in the context of individual patient risk profiles.

Oral Wegovy — MHRA marketing authorisation, 11 June 2026

A tablet formulation of semaglutide at a higher dose, developed for chronic weight management, received MHRA marketing authorisation on 11 June 2026, which the MHRA describes as the UK's first GLP-1 tablet for weight loss and weight management (MHRA announcement). The oral formulation incorporates a permeation enhancer (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate, known as SNAC) that facilitates absorption of semaglutide across the gastric mucosa, a mechanism that differs from the absorption pathway of conventional small-molecule oral medicines.

The MHRA's authorisation of oral Wegovy does not make it immediately available to all UK patients. A marketing authorisation establishes that a medicine is safe, efficacious, and manufactured to appropriate quality standards; it does not determine how the National Health Service funds or provides access to it. That is a separate question, addressed through health technology assessment.

NHS access — pending NICE appraisal

In England, routine NHS funding of a newly authorised medicine for a given indication is conditional on a positive technology appraisal by the National Institute for Health and Care Excellence (NICE). NICE assesses clinical and cost effectiveness using a structured methodology, evaluating the incremental cost per quality-adjusted life year (QALY) gained against a threshold that reflects what the NHS considers a reasonable use of finite healthcare resources. Until NICE publishes a positive appraisal guidance recommending a medicine for NHS use, NHS commissioners in England are not routinely required to fund it, and it will not typically appear on GP prescribing systems as an NHS prescription option.

The MHRA's announcement of 11 June 2026 states that the tablet is not currently available via the NHS and that decisions on NHS use will follow established processes, including a NICE evaluation. Scotland and Wales have their own bodies, the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG), which reach reimbursement decisions on separate timetables; Northern Ireland's Department of Health decides separately whether to adopt NICE guidance. Injectable Wegovy had itself gone through a NICE appraisal process and been recommended for restricted NHS use in England under a specialist weight-management pathway; injectable Ozempic carries a separate set of NICE guidance relating to its type 2 diabetes indication. The availability of an NHS prescription for any licensed form of semaglutide ultimately depends on whether the specific product, at the specific dose, for the specific indication, has a current positive NICE guidance in the relevant UK nation.

Patients seeking semaglutide through the NHS should consult their GP or a specialist weight-management service for current prescribing eligibility. Private prescribing is available for licensed medicines through registered private clinics and online prescribing services regulated by the Care Quality Commission (CQC), but private patients should verify that any prescriber is registered with the General Medical Council (GMC) or General Pharmaceutical Council (GPhC) and operating within those bodies' standards for remote prescribing.

The Human Medicines Regulations 2012 and what they prohibit

The legislative basis for medicines regulation in the UK is the Human Medicines Regulations 2012 (SI 2012/1916), a statutory instrument that consolidated and updated earlier pharmaceutical legislation. These regulations govern who may manufacture, import, distribute, and supply medicinal products in the UK, and they establish the marketing authorisation system through which any medicine must be assessed and approved before it can lawfully be placed on the market for human use. The regulations define a "medicinal product" broadly: a substance or combination of substances presented as having properties for treating or preventing disease in human beings, or any substance or combination of substances which may be used in or administered to human beings with a view to restoring, correcting, or modifying physiological functions by exerting a pharmacological, immunological, or metabolic action.

Under that definition, semaglutide in any presentation (a finished pharmaceutical product in a branded pen, a raw peptide powder, a liquid in a dropper bottle or a transdermal patch) constitutes a medicinal product if it is presented or sold in the context of weight management or other therapeutic purposes. A marketing authorisation is required to place such a product on the UK market. The MHRA holds the register of authorised products. If a product containing semaglutide does not appear on that register with a valid current authorisation for the presentation and indication in question, its supply for human use in the UK is unlawful under the regulations.

"Unlicensed" means that the regulatory pathway required under UK law has not been followed. The MHRA has not reviewed the safety and efficacy evidence needed to support an authorisation, and no competent authority has assessed the Good Manufacturing Practice controls that govern synthesis conditions, sterility testing and shelf life.

The scale of MHRA enforcement in 2025: what the figures cover

In 2025 the MHRA, working with law enforcement partners, seized almost 20 million doses of illegally traded medicines with a potential street value of nearly £45 million. The figure covers every category: almost ten million doses of sedatives and sleeping pills, over four million of painkillers and more than four million of erectile dysfunction treatments. Weight-loss medicines are a much smaller share. The MHRA's Criminal Enforcement Unit seized more than 5,000 illegally traded GLP-1 products and dismantled an illicit facility in Northampton that was making and distributing unlicensed weight-loss jabs (MHRA, 26 January 2026).

Unlicensed GLP-1 products take several forms: counterfeit pens or vials packaged to resemble Ozempic or Wegovy, raw peptide material presented as a finished product, and "research" vials marketed through social media in ways that make intended human use plain. The MHRA's remit covers all of them, because the regulatory test is what a product is and how it is presented and supplied, whatever the seller calls it.

The agency has published public warnings and product alerts through its website at gov.uk/MHRA regarding the illegal sale of medicines. The MHRA's own advice is that products sold illegally online may contain too much or too little of the declared active ingredient, or other harmful substances.

Formulations that fall outside the authorised landscape

The MHRA's authorisations cover specific products in specific formulations. The existence of those authorisations does not extend legal cover to other presentations of semaglutide by analogy. This is a point of some practical importance, because the unlicensed market has generated a range of alternative formulations that have no counterpart in the authorised landscape.

Powders and raw peptide materials

Raw semaglutide peptide sold as a powder, sometimes labelled "research grade" or accompanied by a certificate of analysis from a commercial peptide supplier, does not hold a UK marketing authorisation for any human use. The certificate of analysis issued by a commercial peptide supplier is a quality control document for the material as a research chemical; it is not equivalent to, and does not substitute for, the MHRA assessment process. Under the Human Medicines Regulations 2012, presenting or supplying such a material for a medicinal purpose constitutes placing an unauthorised medicinal product on the market.

Oral drops and nasal formulations

Liquid formulations of semaglutide sold in dropper bottles for sublingual or oral administration, or nasal spray formulations, have not received MHRA marketing authorisation. The oral Wegovy tablet authorised in June 2026 is a specific pharmaceutical product developed by Novo Nordisk and assessed by the MHRA as a defined medicine, not a category approval that extends to any semaglutide-containing liquid or spray. The SNAC permeation-enhancement technology required for meaningful oral semaglutide bioavailability is a patented, formulation-specific mechanism; a simple aqueous semaglutide solution administered sublingually does not replicate it. Products offering such formulations without a marketing authorisation are unlicensed regardless of any claimed bioavailability benefit.

Transdermal patches

Transdermal patches containing semaglutide have appeared in the unlicensed market. No such product holds an MHRA marketing authorisation. The transdermal delivery of peptide molecules of semaglutide's molecular weight faces substantial pharmacokinetic barriers that have not been addressed through any approved pharmaceutical development programme accepted by the MHRA. These products are unlicensed medicinal products under the Human Medicines Regulations 2012.

The pattern common to all of these unlicensed formulations is the same: a product is presented in the context of weight management or metabolic therapy, containing or claiming to contain semaglutide, without the marketing authorisation that UK law requires and without the quality controls that authorisation entails. The MHRA's enforcement activity applies uniformly across all of them.

What the regulatory picture means in practice

Semaglutide's legal position in the UK is clearly defined. Injectable Wegovy is a licensed medicine available by prescription. Oral Wegovy is a licensed medicine as of June 2026, pending NHS funding through the NICE process. Ozempic is a licensed medicine for type 2 diabetes. Everything else, including powders, drops, patches, unlicensed vials and research-grade peptides sold for human use, holds no UK authorisation and is subject to MHRA enforcement.

For a person who has a clinical indication for weight management with a GLP-1 receptor agonist, the appropriate pathway is through a licensed healthcare professional who can assess eligibility, contraindications, and the relative merits of NHS versus private prescribing options. That pathway produces a legal, quality-assured medicine from a regulated supply chain. The unlicensed alternatives offer neither assurance.

Summary: the MHRA authorisations, precisely stated

Semaglutide is legal in the UK in specific, authorised forms. Injectable Wegovy (semaglutide, subcutaneous, once weekly) holds MHRA marketing authorisation as a prescription-only medicine for chronic weight management and has been recommended by NICE for a restricted specialist NHS pathway. Oral Wegovy received MHRA marketing authorisation on 11 June 2026, with NHS availability contingent on a NICE evaluation. Injectable Ozempic holds separate MHRA authorisation for the treatment of type 2 diabetes mellitus.

Outside of those specific authorised products, semaglutide in any form (raw peptide, unlicensed injectable, oral drops, transdermal patches) does not hold a UK marketing authorisation and is subject to MHRA enforcement. The authorised route to semaglutide in the UK is through a licensed prescriber and a regulated pharmacy.